1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well...
1. In this randomized, non-inferiority trial, the omission of surgical axillary staging was noninferior to sentinel lymph node biopsy in...
1. In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), lenvatinib plus...
1. Cooling was found to have a relative risk reduction of 42% and compression had a relative risk reduction of...
1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events...
1. This study describes two cases of malignant monoclonal T-cell lymphoproliferation following ciltacabtagene autoleucel (cilta-cel) Chimeric Antigen Receptor T-cell (CAR...
1. In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with residual human epidermal...
1. Among patients with resectable esophageal cancer, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in improved survival...
1. In this randomized controlled trial, in patients with relapsed or refractory multiple myeloma (MM), combination therapy of talquetamab and...
1. In this randomized controlled trial, cabozantinib significantly improved progression-free survival in patients with progressive pancreatic and extra-pancreatic neuroendocrine tumors....
